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Abstract
Ojectives: Use the established xenograft model of human melanoma C8161.9 to test a
pharmacological approach to effect of the metastasis suppressor KISS1.
Methods: A KISS1 analog was used to inhibit the metastatic development of C8161.9
cells in nude mice. Further experiments were performed to test the validity of the
C8161.9 model and test the connection between KISS1 expression and loss of metastatic
potential. New clones of C8161.9 cells were obtained, with or without KISS1 expression,
and were tested for metastasis formation.
Results: The absence of benefit in survival with the KISS1 analog compared to PBS
prompted us to revisit the C8161.9 model. We found that the cells expressing KISS1 used
in the previous study and obtained by transfection and single cell cloning were defective
for formation of both orthotopic tumor and metastases. In mixing experiments, these cells
could not suppress orthotopic tumor growth of KISS1-negative C8161.9 cells, suggesting
that the suppression of metastasis by C8161.9-KISS1 cells may be intrinsic to the
selected clone rather than related to KISS1 expression. Isolation in soft agar of clones
from parental C8161.9 cells yielded cell populations that phenotypically and
genotypically mimicked the KISS1-positive clone. Also, new clones expressing KISS1
did not show any decrease in metastatic growth.
Conclusions: These data demonstrate the heterogeneity of cell types in the C8161.9 cell
line and the high risk of artifact linked to single cell selection. A different xenograft
model will be necessary to evaluate the use of KISS1 analogs as anti-metastatic therapy.

Keywords: metastasis; metastasis suppressor; KISS1; GPR54; cell line
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Introduction
KISS1 was identified as a metastasis suppressor gene in human malignant
melanoma cells [1, 2]. As opposed to tumor suppressors, metastasis suppressors do not
inhibit the growth of primary tumors, but specifically target the spread of tumor cells to
distant organs and the establishment of secondary lesions. These metastasis suppressors
can interfere with any step of the metastatic cascade, including invasion, angiogenesis,
migration and homing, intravasation, survival and proliferation in a new environment [3].
KISS1 was originally identified in experiments in which transfer of human chromosome
6 to metastatic melanoma cells suppressed metastasis in a mouse xenograft model [1, 2].
The gene was identified by subtractive hybridization and differential display and was
sufficient to suppress the metastatic phenotype of several human cell lines including
breast cancer [4] and ovarian carcinoma [5] in mouse xenograft experiments. In clinical
studies, the absence or reduced expression of KISS1 has been linked to higher grade
and/or poor prognosis in several malignancies including melanoma [6, 7], carcinoma of
the ovary [8, 9], stomach [10, 11], urinary bladder [12] esophagus [13], lung [14] and
pancreas [15, 16].
KISS1 encodes a secreted protein that is sequentially proteolytically processed to
generate multiple polypeptides ranging from 54 to 10 amino acids called kisspeptins (KP)
that share the same amidated C-terminus [17-20]. Although other peptidic fragments are
generated during this maturation process, the biological activity of KISS1 is thought to
reside with KP. Their action is mediated through binding to and activation of GPR54, a G
protein-coupled receptor (GPCR), also known as AXOR12 and hOT7T175 and coupled
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to Gαq [17-20]. GPR54 activation by kisspeptins was shown to block chemotaxis to fetal
bovine serum (FBS), activate extracellular signal-regulated kinase (ERK1/2), induce
formation of stress fibers, phosphorylate focal adhesion complex, decrease expression of
matrix metalloproteinase 9 (MMP-9) and reduce cell proliferation in receptor
transfectants [17, 19, 21]. We have shown previously that activation of GPR54 by
kisspeptin-10 (KP10) inhibited chemotaxis induced by stromal cell derived factor 1
(SDF-1)/CXCL12 and its receptor CXCR4 [22], a mechanism shown in several models to
be involved in the migration of CXCR4+ tumor cells to the organs that secrete its ligand
such as the lungs, liver, brain and bones [23]. Activation of GPR54 suppressed Akt
phosphorylation by CXCR4 [22]. We recently demonstrated a number of cellular events
resulting from GPR54 activation, including suppression of the phosphorylation of Akt
following activation of their respective receptor tyrosine kinase (RTK) by epidermal
growth factor (EGF) and insulin, induction of apoptosis, expression of TNF-α [24], as
well as profound modifications of the actin cytoskeleton through RhoA and Rhoassociated kinase (ROCK) activation [25].
The human melanoma cell line C8161.9 was used for the initial description of the
anti-metastatic properties of KISS1 [1]. In xenograft experiments in nude mice, the
secretion of KP by a C8161.9 clone was shown to have a remarkable capacity to reduce
metastasis to the lungs, eyes, bones and kidneys by keeping tumor cells quiescent after
dissemination and seeding in secondary organs [26]. Furthermore, this model is
especially interesting in that, although the metastatic growth of C8161.9 cells is
suppressed by the secretion of KPs, the cells do not express GPR54 [26]. This suggests
that KPs have the capacity to act on the microenvironment of tumor cells rather than on
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the tumor cells themselves [27]. This property could establish KPs or synthetic analogs as
prime candidates as a therapeutic option for the treatment of metastatic disease as it could
be used even after dissemination from the primary tumor has occurred, a property that
would be especially desirable for the treatment of melanoma. To test this hypothesis, we
used a recently developed analog of KP with vastly improved stability in order to inhibit
metastatic growth of C8161.9 cells. The results of these experiments prompted us to
revisit the C8161.9 xenograft model. We found that the remarkable anti-metastatic
properties of KISS1 in that model rely largely on an artifact of clonal selection rather
than on KISS1 expression.

Methods
Cell lines and transfections: Parental C8161.9, C8161.9 transfected with an empty
pcDNA3 plasmid, selected with G418 and then transduced with a lentivirus encoding
EGFP (C8161.9-pc3) and C8161.9 tranfected with pcDNA3 coding for KISS-FLAGMetastin (KFM, a version of KISS1 incorporating a FLAG tag), cloned and then
transduced with a lentivirus encoding EGFP (C8161.9-KFM) were previously described
[26]. Whereas C8161.9-pc3 cells are a polyclonal population derived from the parental
cells by antibiotic selection (G418), C8161.9-KFM cells are a single cell clone obtained
by antibiotics selection (also G418) followed by limiting dilution and screening for
secretion of KISS1. These different cell lines were kindly provided by Dr. Danny Welch
(UAB, Birmingham, AL).
The open reading frame coding for KFM was amplified by PCR from the DNA purified
from C8161.9-KFM cells and subcloned in pcDNA3.1 (Invitrogen) with G418 or
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hygromycin selection marker. Correct sequence was verified by Sanger sequencing.
Parental C8161.9 cells (for pcDNA3.1-G418) and C8161.9-pc3 (for pcDNA3.1-Hygro)
were transfected using Lipofectamine complemented with LTX reagent (Invitrogen,
Carlsbad, CA) according to manufacturer’s instructions and selected with the appropriate
antibiotics for 2 weeks before cloning.

KP analogs: FTM145 ((4-fluorobenzoyl)-Phe-Gly=Leu-Arg-Trp-NH2) and FTM145carboxylate (non-amidated) were previously described [28]. Lyophilyzed compounds
were dissolved in DMSO at 12.5 mM, diluted in PBS at 250 µM and sterile filtered.
Single-use aliquots were prepared for in vivo experiments.

Western blotting: Western blotting was performed as previously described [22]. Briefly,
transfectants of 293 cells with stable expression of GPR54 were seeded in 35 mm plates,
starved overnight in serum-free medium, then exposed to log dilutions of KP10, FTM145
or FTM145-carboxylate for 5 min. Cell lysates were prepared in SDS sample buffer.
Western blots were incubated first with antibodies to total ERK1/2 or phospho-ERK1/2
(Cell Signaling Technology, Danvers, MA), then with secondary antibodies labeled with
peroxidase (Jackson ImmunoResearch, West Grove, PA). Western blots were finally
incubated with a chemiluminescent substrate (ECL-Plus, Amersham, GE-Healthcare,
Piscataway, NJ) and analyzed with a LAS-4000 digital imaging system (GE-Healthcare).

Soft agar assay: A bottom layer consisting in 5 mL of 2x Dulbecco’s Modification of
Essential Medium/Ham’s F-12 (DMEM/F-12) mixed at 40°C with 5 mL of a 1% solution
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of agar noble (BD Biosciences, Sparks, MD) in H2O and layered in a 100 mm tissue
culture dish. For the top layer, 1.5 x 104 cells were added to 5 mL of 2x DMEM/F-12
mixed with 5 mL of a 0.7% solution of agar in H2O (0.35% final concentration of soft
agar). After solidification, 10 mL of complete liquid medium was added. Medium was
replaced every 3 days for 4 weeks. Colonies were photographed using an inverted
microscope or an ImageQuant LAS 4000 digital imaging system (GE Healthcare,
Piscataway, NJ). For clone isolation, colonies were extracted using 1000 µL sterile tips
and placed in warm trypsin-EDTA in medium. Repeated pipeting was used to dissociate
the colonies and the cells were plated in tissue culture dishes in complete growth
medium.

Detection and quantification of secreted KFM by ELISA: Conditioned media were
prepared by seeding 5 x 105 cells in 2 mL of complete growth medium in 35 mm dishes.
Cells were grown for 48 hours at 37°C in 5% CO2. Conditioned media were then
collected and cleared by centrifugation at 2,000 g for 5 min. ELISA plates (Maxisorp,
Nalge-Nunc, Rochester, NY) were coated for 1 h at room temperature (RT) with 100 µL
a mouse monoclonal antibody specific for KISS1 (clone 1A5 or 6A4, kindly provided by
Dr. MaryAnn Accavitti-Loper, UAB, Birmingham, AL) diluted at 10 µg/mL in PBS.
After blocking for 1 h with TBS containing 5% Bovine Serum Albumin (BSA), antigen
capture was performed with 200 µL of conditioned medium for 1.5 h at RT, followed by
detection with M2 anti-FLAG antibody conjugated to peroxidase (Sigma, St Louis, MO)
diluted 1:5000 in TBS 1% BSA. The substrate (200 µL, SigmaFast, Sigma) was added
for 30 min and the reaction was stopped with 50 µL of 1 N HCl. Absorbance was
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measured at 490 nm using a spectrophotometer (BioTek, Winooski, VT). Background
was determined using a conditioned medium obtained with C8161.9-pc3 cells and was
identical to the signal obtained with TBS-BSA alone.

Detection of intracellular KISS1 by flow cytometry: Cells were detached with
Trypsin-EDTA, fixed in PBS containing 4% paraformaldehyde (PFA) for 1 h at RT,
washed 4 times in PBS, then permeabilized for 5 min in PBS containing 0.1% Triton X100. PFA was quenched with 100 nM glycine in PBS for 30 min, followed by blocking in
PBS containing 1% BSA and 10% goat serum for 1 h at RT. Cells were incubated with
the 1A5 anti-KISS1 antibody or a control IgG (SouthernBiotech, Birmingham, AL) (both
2 µg/mL in PBS 1% BSA 10% goat serum) for 90 min at RT, followed by overnight
incubation at 4°C with F(ab’)2 goat anti-mouse IgG labeled with phycoerythrin (10
µg/mL, Jackson ImmunoResearch, West Grove, PA). Samples were analyzed on a FACS
Sort flow cytometer and Cell Quest software (BD Biosciences, San Jose, CA).

Quantitative real-time PCR (qPCR): Total RNA was extracted from cell lines using the
mirVana miRNA isolation kit (Ambion, Austin, TX) and quality was assessed using a
RNA 6000 Nano kit and a Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA).
For cDNA synthesis, 500 ng of RNA was used with the Enhanced Avian First Strand
Synthesis kit (Sigma). QPCR was performed on a Lightcycler 480 (Roche, Indianapolis,
IN) with HotStartIT SYBR Green qPCR mastermix (USB, Cleveland, OH) using the
following primers: Forward 5’-actcactggtttcttggcagc-3’, Reverse 5’-accttttctaatggctcccca3’. Cycling conditions were 95 oC for 3min, 40 cycles of 95 oC for 10sec, 60 oC for 20sec
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72 oC for 30sec, followed by a melting curve from 45 oC to 95 oC. Standard curve was
obtained using serial dilutions of the pcDNA3.1-KFM plasmid. Jurkat cells transfected
with GPR54 were used as a negative controls because the presence of very low
concentrations of KP was shown to induce apoptosis in these cells.

In vivo experiments: 3-4 weeks old Nude mice (Harlan, Indianapolis, IN) were used for
all experiments. For orthotopic tumor formation, mice were injected intradermally with 2
x 105 cells in 50 µL Hank’s balanced salt solution (HBSS) using a Hamilton syringe and
a 30-gauge needle. Mice were euthanized after 5 weeks and tumor size was measured
using a caliper. For metastatic tumor formation, 5 x 105 cells were injected in the lateral
tail vein in 100 µL of HBSS using an insulin syringe and a 31-gauge needle. Antimetastatic activity of FTM145 was assessed by injecting 150 µL of a 250µM solution
diluted in PBS, an amount expected to generate an estimated peak concentration of about
20 µM in the extracellular space in 15-20 gram animals. Mice were euthanized after 5
weeks or when moribund for survival experiments. All experiments were conducted in
accordance with the guidelines of the Institutional Animal Care and Use Committee at
Thomas Jefferson University. Animals were dissected and lungs were fixed in PBS
containing 4% PFA for 24 hours before being processed for histology studies. Sections
were stained with hematoxylin and eosin.and scanned using a ScanScope XT scanner
(Aperio Technologies, Vista, CA). Images were visualized with Spectrum software
(Aperio).
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Comparative Genomic Hybridization (CGH) array: 0.5µg of DNA from cell lines,
and Female control gDNA (Promega, Madison, WI) were digested by AluI and RsaI
restriction enzymes, then labeled with Cy5 and Cy3 respectively using the Enzymatic
Labeling kit from Agilent according to the manufacturer’s protocol. Samples were
combined, heat-denatured and mixed with COT-1 DNA (Roche), blocking buffer and HiRPM buffer (both from Agilent) before being hybridized to an Agilent 4x44k human
CGH microarray for 24 h at 65oC. Washing was performed as recommended by the
vendor, and the arrays were scanned using an Agilent DNA Microarray Scanner. Data
were processed with Feature extraction Software version 10.7.3.1 and analyzed in DNA
Analytics version 4.0.76 (Agilent Technologies)

Statistics: Averages of measureable variables were compared between experimental
groups using Student’s t-test with a 95% confidence interval. P values <0.05 were
considered significant. The survival experiment was analyzed using the Kaplan-Meier
method. All analyses were performed with Prism 3.0 (GraphPad. La Jolla, CA).

Results
Injection of a KP analog does not reduce metastasis of C8161.9 cells.
We used an analog of KP to inhibit the metastatic growth of C8161.9 cells in nude
mice to determine whether pharmacologic administration of KP could reproduce the antimetastatic effect seen when expression was programmed in tumor cells. Using the same
xenograft model, the secretion of KP by clones of C8161.9-KFM cells was previously
shown to inhibit metastasis to the lungs by more than 90% [26]. This established model
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used the polyclonal C8161.9-pc3 cells as positive control for metastasis. Both pc3 and
KFM cells expressed EGFP to allow ex vivo localization of tumor cells in organs. We
selected the analog FTM145 because of its resistance to proteolytic cleavage and its
extended half-life in mouse serum [28]. We first confirmed that the injectable solution of
the C-amidated version of FTM145 was fully active in vitro. Serial dilutions of KP10,
FTM145 and the barboxylated version of FTM145 were added to HEK-293 cells
expressing GPR54 and cell lysates were analyzed by western blotting for activation of
ERK1/2. KP10 and FTM145 were equally potent, with full phosphorylation of ERK
achieved at 1 nM of each ligand. In contrast, the non-amidated FTM-145 only induced
significant activation of GPR54 at 1 µM (Figure 1A).
Two groups of 20 nude mice each were injected on day 1 with metastatic C8161.9pc3 cells (i.v.). FTM145 (amidated, n = 20) or PBS alone (n = 20) were administered
daily through subcutaneous injection. In this survival experiment, FTM145 did not
provide any advantage compared to injection of PBS (Figure 1B). Upon dissection, all
animals showed extensive metastasis to the lungs (comparable to the animal shown in
Figures 3B and 3C, pc3 panels), irrespectively of the treatment received, indicating that
injection of a KP mimetic was incapable of inhibiting metastasis of C8161.9.

C8161.9-KFM cells differ phenotypically from original C8161.9 cells
In an attempt to reconcile the data showing the absence of in vivo activity of
FTM145 with the previously published data showing the strikingly reduced metastatic
potential of C8161.9 cells secreting KPs, we conducted a series of experiments
comparing the in vitro and in vivo phenotypes of different types of C8161.9 cells: 1)
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parental C8161.9 cells, 2) C8161.9 transfected with an empty pcDNA3 plasmid, selected
with G418 and then transduced with a lentivirus encoding EGFP (C8161.9-pc3) and 3)
C9161.9 tranfected with pcDNA3 coding for KFM, cloned and then transduced with a
lentivirus encoding EGFP (C8161.9-KFM). C8161.9-pc3 and C8161.9-KFM were used
in previously published in vivo experiments [26] and C8161.9-pc3 were used as
metastatic cells throughout the current study in order to remain consistent with published
work.
Whereas both parental C8161.9 (not shown) and C8161.9-pc3 (Figure 2A)
consisted of a vast majority of small cells and a minority of larger cells, C8161.9-KFM
were much larger and very homogeneous in size and morphology (Figure 2A). The 3 cell
types were tested for their capacity to form colonies in soft agar. In 3 separate
experiments, C8161.9-pc3 cells did not form any colonies, in contrast with C8161.9KFM cells which consistently established large numbers of colonies (Figure 2B). The
parental C8161.9 cells formed a few colonies, but these colonies were similar in size to
those made by KFM cells. Seven colonies (most likely clones, each one originating from
a single cell based on the distance separating the colonies as well as their spherical
geometry) were isolated from the soft agar plate with a pipet tip and expanded in culture.
All 7 clones (agar clones AC1-7) were composed of large cells morphologically similar
to C8161.9-KFM cells, as shown in Figure 2A for AC4 and AC5. After expansion, these
clones maintained their capacity to form colonies in soft agar, AC5 being as efficient as
KFM cells (Figure 2C). All cell types displayed the same growth rate in normal culture
condition with a doubling time of 24 hours (not shown). These data suggest that the
parental C8161.9 cells contain multiple populations with varying behaviors, including a
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few larger cells capable of establishing colonies in soft agar. It appears these cells were
preferentially selected in the cloning process leading to the isolation of C8161.9-KFM
cells and also seem to have been depleted (partially or completely) during the selection of
the C8161.9-pc3 cells.
C8161.9-KFM cells were previously described as being able to establish
orthotopic tumors with an efficiency similar to C8161.8-pc3 cells [26]. However, 4
weeks after intradermal inoculation of 2 x 105 cells, the average size of the tumors
formed by C8161.9-KFM (19 ± 17 mm3, n=3) cells was less than 10% of the size of
tumors made by C8161.9-pc3 cells (400 ± 40 mm3, n=3) and even several times smaller
than tumors made after inoculation of 2 x 104 pc3 cells (137 ± 81 mm3, n=3) (Figure 3A).
To test the possibility that local secretion of KP is responsible for that reduction in
growth potential, we performed an experiment in which 2 x 105 KFM cells were mixed
with 2 x 104 pc3 cells and injected intradermally. The average volume of the tumors
made by this mixed population (198 ± 92 mm3, n = 3) was not significantly different
from the volume of tumors made by 2 x 104 C8161.9 pc3 cells alone (Figures 3A),
indicating that, despite an initial numerical excess, C8161.9-KFM cells were unable to
inhibit the growth of C8161.9-pc3 cells.

Soft agar clones reproduce the phenotype of C8161.9-KFM cells
After having established that the soft agar clones obtained from the original
C8161.9 cells behaved similarly to KFM cells in vitro, we conducted experiments to test
whether they also exhibited a decreased metastatic potential. Nude mice (n = 4 for each
cell type) received an i.v. injection of C8161.9-pc3, C8161.9-KFM or one of 5 soft agar
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clones (AC2, 3, 4, 5 and 7). After 5 weeks, mice injected with pc3 cells were visibly sick
whereas all other mice appeared completely healthy. Upon dissection, mice injected with
pc3 cells showed extensive metastasis to the lungs (Figure 3B and Table 1). All other cell
types showed a dramatically reduced metastasis with no or very few visible lesions
(Figure 3B). Lungs of all animals were fixed in PFA and sections were stained with
hematoxylin and eosin. Analysis of these sections confirmed the dramatic reduction of
metastasis observed with the KFM cells and AC2, 3, 4, 5 and 7. Representative fields of
sections are shown in Figure 3C. To rule out the possibility that the decrease of metastatic
potential by these clones was due to endogenous expression of KISS1, we performed
qPCR. KISS1 mRNA could be detected at high levels in the transfected KFM cells but
was absent or expressed at very low level in the soft agar clones (Figure 3D) as well as
Jurkat cells transfected with GPR54 that do not express KISS1 and were shown to be
extremely sensitive to exogenous KP10 [24]. These data indicate that clonal selection in
soft agar did not select for cells overexpressing KISS1. These data indicate that a minor
subpopulation of cells present in the parental C8161.9 cell line phenotypically resembles
C8161.9-KFM cells (both in morphology and in tumor-forming potential) without
expressing KISS1. They also illustrate an inverse relationship between the clonogenicity
in soft agar and the capacity to form tumors in nude mice.

Single cell cloning of C8161.9 cells is biased toward large cells similar to KFM cells.
Since the KP-expressing cells already available displayed a phenotype that did not
represent the original C8161.9 cell line, we sought to prepare new transfectants
expressing KISS1 using parental C8161.9 cells or C8161.9-pc3 cells. In order to remain
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as close as possible to the original model, we designed two parallel strategies. First, in
order to derive new transfectants from cells with a tested and well established metastatic
potential, we used as host the C8161.9-pc3 transfectants that have previously been used
in animal experiments, including those described above. Since these cells were already
resistant to G418, we used the hygromycin pcDNA3 vector to stably introduce KFM in
these cells. In the second strategy, we established new transfectants from the parental
C8161.9 cell line using G418 as a selection marker in order to exactly reproduce the
conditions that presided over the creation of the pc3 and KFM cells described and
employed previously. Since every single cell injected to the animals for the xenograft
studies must secrete KISS1, antibiotics selection is not sufficient and single cells cloning
is required to guarantee homogeneity of the cell population. Cells were transfected with
pcDNA3.1-KFM-G418 (for parental C8161.9) or pcDNA3.1-KFM-Hygro (for C8161.9pc3), both plasmids containing an insert coding for KFM identical to that employed in
Nash et al. [26]. After selection with G418 (for parental cells) or hygromycin (for
C8161.9-pc3 cells), stable KFM transfectants were obtained by single cell cloning. We
first used limiting dilution in 96-well plates, which produced only 2 clones out of 6 plates
(576 wells) for the parental cells and 3 clones out of 12 plates (1152 wells) for the pc3
cells. Each of these clones consisted of large cells similar to the C8161.9-KFM cells used
previously (not shown). The very low number of clones obtained and the recurring “large
cell” phenotype indicate that C8161.9 cells are very difficult to clone and that standard
protocols are heavily biased toward the selection of large cells that seem to be the only
ones capable of growing at very low density. Because this bias increased the risk of
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selecting cells that functionally did not represent the C8161.9 cell line as a whole, these
few clones were discarded without further study.
To avoid this problem and obtain multiple clones representing the diversity of
C8161.9 cells, we used a “feeder cell” approach in which transfected cells (10 cells / mL)
were mixed with non-transfected C8161.9 cells (1 x 104 / mL) before seeding (100 µL
/well), so that transfectants could establish supportive contacts with neighboring cells.
After 6 days of co-culture in complete medium without selection antibiotics, cells were
about 50% confluent. At this point, G418 or hygromycin was re-introduced in the growth
medium, eliminating all the non-transfected cells in 2-3 days. Resistant clones were left
to expand and were detected under an inverted microscope. Supernatants were collected
and tested by ELISA for presence of secreted KFM. More than 125 clones were obtained
from five 96-well plates, indicating that this protocol allowed the isolation of positive
clones with no or minimum selective pressure other than the selection antibiotic. The
clones displayed a variety of morphologies, most consisting of small cells and a few
composed of large cells, thus demonstrating the heterogeneity of the original cell line (not
shown).
Clones positive for secretion of KFM (over 40) were expanded and further tested
for expression of KFM by flow cytometry and semi-quantitative ELISA. Flow cytometry
allowed the selection of genuine single cell clones with homogeneous expression of
intracellular KFM (Figure 4A). Some clones displayed expression as high as the original
C8161.9-KFM clone. Secretion of KFM was assessed by semi-quantitative ELISA.
Representative clones are shown in Figure 4B.
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New C8161.9-KFM clones show normal metastatic potential
The metastatic potential of the new C8161.9 clones expressing high levels of
KFM was evaluated in nude mice. A total of 17 clones were tested, either as individual
clones (8 clones) or as pools of 2 to 4 clones (9 clones in 3 pools) (Table 1). Two or 4
nude mice were injected intravenously with 5 x 105 cells and were sacrificed after 5
weeks. The lungs of mice injected with large cell variants (clones 2E8 and 5C6) showed
strongly decreased metastasis compared to mice injected with C8161.9-pc3 cells, whereas
mice injected with clones composed of small cells that resembled the parental line
showed extensive metastasis similar to that obtained with pc3 cells, independently of the
KFM expression level (Figure 4C and Table 1). Although the number of animals used for
each clone is small, data were very consistent for each clone and within each phenotype
(small vs. large cells). Only one small cell clone (4F12) showed a decreased number of
metastatic lesions (although most lesions were large) (Figure 4C). This data demonstrate
that the C8161.9 cell line consists of multiple subpopulations with different metastatic
potential and that individual clones can exhibit in vivo clonogenic activities resulting in a
metastatic potential ranging from very high to very low, independently of KP expression.

Morphological differences correlate with genomic changes in C8161.9 cells evident
following selection.
Having established a correlation between cell morphology and cell phenotype in
vitro and in vivo, we hypothesized that this phenotypic heterogeneity could also be
evidenced at a genetic level. We used CGH with high-resolution DNA microarrays to
detect DNA copy number variations (CNV; gains and losses) in nine different C8161.9
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variants: parental C8161.9, C8161.9-pc3 and the new KFM clone 6F10 for the small cell
/ highly metastatic category, C8161.9-KFM (the original clone used in Nash and
colleagues), and soft agar clones AC2, 3, 4, 5 and 7 for the large cell / poorly metastatic
category. Data analysis indicated that, although some CNV shared by all cell types from
both groups (gain of chromosome 3q, loss of 9p and 17q) indicate a common origin,
members of the large cell group shared additional CNV that were absent in small cells
and could not be detected in parental C8161.9 cells or C8161.9-pc3 cells, such as loss of
chromosomes 4, 5p, 5q, 9p and 17p, as well as gain of chromosomes 9q and 17q (Figure
5). The fact that these CNV could not be detected in the parental cell line correlates with
the fact that the large majority of the cells in the C8161.9 cell line consists of small cells
and that the large cell variants represent a minor population. These data also show that
the C8161.9-KFM clone used in the previous study differed from the original C8161.9
cell line at several genomic and phenotypic levels in a manner unrelated to KISS1
expression.

Discussion
Among the members of the family of metastasis suppressors, expression of KISS1
was shown to confer dramatic inhibition of the post-migratory step of the metastatic
process. The initial studies for characterizing the mechanisms responsible for the antimetastatic effect assumed an autocrine mechanism of action whereby KP secreted by
tumor cells would bind and activate GPR54 on the same cells, thereby inhibiting cell
migration as shown with the B16 model of melanoma [19]. The C8161.9 model indicated
instead that expression of GPR54 on the tumor cells was not required for KISS1
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suppression of metastasis formation [26]. The observation that secretion of KISS1 by
C8161.9 melanoma cells maintained the cells in a prolonged state of dormancy opened
new perspectives toward the therapeutic use of KP molecular analogs that could be used
to treat metastatic disease even after the initial spread of tumor cells. Since these findings
also suggested that the target of KISS1 was the microenvironment, the C8161.9 model
represented an appropriate system to investigate this hypothesis. However, administration
of high concentrations of a fully active KP10 analog with vastly improved resistance to
proteolytic degradation failed to reduce metastasis of C8161.9 cells in nude mice. Also,
C8161.9-KFM established orthotopic tumors much more slowly than control C8161.9pc3 cells and failed to inhibit the growth of pc3 when locally co-injected with a 10:1
excess. Although these data could be explained (insufficient local concentration of the
analog, action of KISS1 mediated by a proteolytic fragment other than KP, KFM cells
quickly outgrown by pc3 cells in the mixing experiment), they together prompted us to
reconsider the validity of the C8161.9 model.
Here we present evidence that the C8161.9-KFM previously described as being
poorly metastatic shared in vitro features with a cell population present at low frequency
(7 clones obtained in soft agar culture from 1.5 x 104 cells) that could be derived from the
parental cell line. Although it also exhibited some level of internal heterogeneity, as a
whole, this sub-population consisted of larger cells that had the capacity to form colonies
in soft agar, could grow as single cells in vitro, had the same in vitro growth rate as
smaller cells, but grew very poorly in vivo when grafted in nude mice, even in the
absence of KISS1 expression. By contrast, the predominant population of C8161.9 cells
were smaller, did not form colonies in soft agar, could not be cloned using standard
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limiting dilution protocols, but were highly tumorigenic in mice. Based on these
differences in growth properties, standard selection procedures using selectable markers
and single cell cloning favor the outgrowth of the non-metastatic population. These two
distinct cell populations (large and mostly small cells) also segregate in two different
categories at the genomic level, thus mirroring and substantiating the phenotypic
differences. The very strong bias toward the selection of large non-metastatic / nontumorigenic cells during the cloning process is most likely the reason for the previous
description of the anti-metastatic effect of the secretion of KFM. This was confirmed by
showing that multiple new clones obtained without the bias of that selective pressure and
expressing high levels of KISS1 maintained the metastatic potential of the parental cell
line.
Our data do not necessarily disprove that KISS1 is a metastasis suppressor in
melanoma and other cancers, even though its role in the C8161.9 xenograft model
appears to be unclear. Indeed, numerous studies investigating the expression of KISS1
and GPR54 in human samples suggest that this system plays a role in a number of
malignancies, although a more limited one that what was suggested by the C8161.9
model. Some studies also support the hypothesis of an effect of KISS1 on the
microenvironment, especially on angiogenesis. In particular, KISS1 was shown to trigger
vasoconstriction by acting on smooth muscle cells [29]. Another recent study indicated
KISS1 signaling in endothelial cells and the resulting inhibition of angiogenesis [30]. The
results presented here show that the C8161.9 xenograft model does not constitute an
appropriate system to investigate the mechanism of action of KISS1. They especially
highlight the risk of experimental artifacts resulting from the selection of single cell
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clones from a cell line after transfection. When cloning is necessary – as it is in the case
of selection based on the expression of a secreted factor – great care should be taken to
characterize the clones to prove that they faithfully represent the original cell population,
both in vitro and in vivo. In that respect, the high resolution CGH employed here
represents a method of choice.
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Table 1: Metastatic potential of C8161.9 clones correlates with morphology and
genomic changes rather than with expression of KISS1
KISS1

Morphology

C8161.9 parental

-

small

C8161.9-pc3

-

small

++++

C8161.9-KFM

+

large

+/-

2

AC2

-

large

+/-

2

AC3

-

large

-

2

AC4

-

large

+/-

2

AC5

-

large

+

2

AC7

-

large

+

2

2E8

+

large

+/-

5C6

+

large

+/-

1A4

+

small

++++

4F12

+

small

++

3H9

+

small

++++

6B6

+

small

++++

3B8

+

small

++++

6F10

+

small

++++

Pool 1 (2E7+5A2+1A5)

+

small

++++

Pool 2 (3F4+1F2+5H2+4H11)

+

small

++++

Pool 3 (3A3+4G9)

+

intermediate

++++

Metastases

CGH type
1

1

The amount of metastasis was measured using the Aperio digital pathology system and is
indicated as follows: - : no visible metastasis; +/- : 0 or 1 very small metastatic lesion
(less than 10 cells) per section; + : 1-5 small lesions (less than 20 cells) per section,
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representing less than 1% of the surface area of the lung tissue in the section; ++ : 1-10
lesions per section, representing in total less than 10% of the surface area; +++ : multiple
lesions representing 10-25% of the surface area; ++++ : multiple lesions representing in
total more than 25% of the lungs surface area (often more than 50%). CGH types 1 and 2
refer to the typical profiles illustrated in Figure 5.
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Figure legends
Figure 1: Injection of a KISS1 mimetic does not inhibit metastasis of C8161.9 cells
in xenograft experiments. A. KP10 and C-ter-amidated FTM145 activated GPR54 in
HEK-293 transfectants with similar potency as demonstrated by phosphorylation of
ERK1/2. B. Daily subcutaneous injections of FTM145 did not suppress metastasis in
nude mice inoculated with C8161.9 cells and did not offer any survival benefit compared
to PBS as shown by Kaplan-Meier analysis.

Figure 2: C8161.9-KFM cell clone differs morphologically and phenotypically from
the majority of the parental cell line. A. C8161.9-pc3 cells and the parental cell line
(not shown) consisted mostly of small cells, whereas the poorly metastatic C8161.9-KFM
clone previously described was homogenously constituted of larger cells. Clones isolated
in soft agar culture from the parental C8161.9 cell line shared similarly large size. B.
C8161.9-KFM cells, but not C8161.9-pc3, developed large numbers of colonies in soft
agar. In contrast, parental C8161.9 cells only formed 7 colonies that were isolated and
amplified (AC1-7). Images were taken using an inverted microscope with 10x objective.
C. After in vitro amplification, clones isolated in soft agar from parental C8161.9 cells
maintained the capacity to for colonies in soft agar, with an efficiency ranging from
moderate (AC4) to as high as C8161.9-KFM cells (AC5). Pictures of the whole plates
were taken with a GE LAS4000 imaging system.

Figure 3: C8161.9 soft agar clones replicated the in vivo phenotype of C8161.9-KFM
cells without KISS1 expression. A. C8161.9-KFM cells exhibited a strongly reduced
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capacity to form orthotopic (intradermal) tumors in nude mice and did not suppress the
growth of co-injected C8161.9-pc3 cells. Tumors were measured 4 weeks post-injection.
Indicated P values were calculated using Student’s t-test with a 95% confidence interval.
B and C. AC clones showed a reduced capacity to form lung metastases similar to
C8161.9-KFM cells. Mice were injected in the tail vein with C8161.9-pc3, C8161.9KFM, AC2, AC3, AC4, AC5 or AC7 cells. After 5 weeks, lungs showed extensive
metastasis in mice inoculated with pc3 cells but no or very few (arrows) visible
metastatic lesions in mice inoculated with KFM or AC cells (B) Images are from one
representative mouse out of 4 for each clone. Sections of the lungs confirmed that both
the number and the size of metastatic lesions (small lesions indicated by arrows) were
strongly reduced with KFM or AC cells compared to pc3 cells. Boxed regions of the lowmagnification pictures are shown in the right panel. Representative fields out of 4 slides
for 4 identical mice for each clone. D. Inhibition of the metastasis potential of AC cells is
not related to endogenous KISS1 expression as demonstrated by the absence of detection
of KISS1 transcripts by qPCR.

Figure 4: Metastatic potential of new C8161.9 clones is independent from KISS1
expression. New clones of C8161.9 cells expressing KFM displayed a wide range of
metastatic potential related to cell morphology but independent of KFM expression.
Multiple new C8161.9 single cell clones were derived after transfection with pcDNA3.1KFM and limiting dilution using non-transfected feeder cells. A. These new clones were
tested by flow cytometry for expression of intracellular KFM using a mAb specific for
KISS1 (1D5). The histograms show for each clone a single population with a staining

32
intensity similar to the previously described C8161.9-KFM cells. B. Semi-quantitative
ELISA for KFM secretion was performed on conditioned media obtained with new KFM
clones (shown: clones 2E8, 4F12, 5G9, 1A4, 6F10 and 6B6) in comparison to 2
conditioned media obtained with the original C8161.9-KFM clone previously described.
Results showed similar levels of secretion of KFM for the different clones. C.
Representative sections of lungs from mice inoculated in the tail vein with new KFM
clones and collected after 5 weeks. Clones consisting of large cells similar to KFM cells
(e.g. 2E8) had strongly reduced metastasis whereas clones consisting of smaller cells
similar to pc3 cells (e.g. 6F10) maintained a metastatic potential similar to C8161.9-pc3
cells. Clone 4F12 had intermediate metastatic potential with fewer but large metastatic
lesions. Boxed regions of the low-magnification pictures are shown in the right panel.

Figure 5: Cell morphology and phenotype correlate with genomic changes among
C8161.9 cells. CGH microarray analysis was performed on small cell clones (e.g. 6F10),
large cell clones (e.g. original C8161.9-KFM and AC2), C8161.9-pc3 cells and the
parental C8161.9 cell line. Data analysis revealed the strong similarity in CNV between
large cells as well as the similarity between small cells, pc3 cells and the parental cell
line. However, large cells diverged from small cells, pc3 and parental C8161.9.
Chromosomes 3, 4, 5, 9 and 17 were the most discriminating. Losses (deletions) are
indicated in green and gains (amplifications) are indicated in red.

